Clinical Trials

DelMar Pharmaceuticals  , a biopharmaceutical company focused on the development of new cancer therapies, announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3). "IRB approval is an essential step in initiating patient enrollment in our Phase 3…
Nutra Pharma Corporation , a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a collaboration with the University of Maryland Bioprocess Scale-Up Facility (BSF) to…
Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular compan announced positive data from its Phase 2 NODE-1 trial evaluating etripamil, a novel, potent, fast-acting and short-acting calcium channel blocker in development for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT), a potentially debilitating cardiac arrhythmia. The data…
Lexicon Pharmaceuticals announced additional positive data from the Phase 3 inTandem1 study.                                    It was previously announced that both doses of sotagliflozin achieved the primary endpoint of the inTandem1 study, showing statistically significant reductions…
POXEL SA , a biopharmaceutical company focused on the development of innovative drugs to treat metabolic diseases, including type 2 diabetes, announced today positive top line Phase 2b data results for Imeglimin for the treatment of type 2 diabetes in Japan. The randomized, double-blind, placebo-controlled study of Imeglimin administered twice-daily…
Page 1 of 24

Subscribe To Our Newsletter

Security Q:How many eyes has a typical person? (ex: 1)
Name:
Email: